Literature DB >> 23228547

Selective serotonin reuptake inhibitors and malformations: case closed?

Gideon Koren1, Hedvig M E Nordeng.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely used by pregnant women due to the high rates of depression among reproductive-age women. Several studies based on administrative databases reported an increased risk of cardiac malformations among infants of pregnant users. This has caused anxiety and fears among expecting women and their physicians, often leading to discontinuation of much-needed therapies. Recent decisive evidence documented a similar higher risk of cardiac malformations among depressed women not taking SSRIs during pregnancy. The most likely reason is ascertainment bias, with depressed women, treated or untreated, undergoing significantly more diagnostic tests in their children. These data strongly support the view that SSRIs do not increase the risk of cardiovascular malformations.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23228547     DOI: 10.1016/j.siny.2012.10.004

Source DB:  PubMed          Journal:  Semin Fetal Neonatal Med        ISSN: 1744-165X            Impact factor:   3.926


  5 in total

1.  Promise and peril: Dissemination of findings from studies of drugs used in pregnancy and their association with birth defects.

Authors:  Stephen W Patrick; William O Cooper
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-07-08

2.  Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study.

Authors:  Anthony Wemakor; Karen Casson; Ester Garne; Marian Bakker; Marie-Claude Addor; Larraitz Arriola; Miriam Gatt; Babak Khoshnood; Kari Klungsoyr; Vera Nelen; Mary O'Mahoney; Anna Pierini; Anke Rissmann; David Tucker; Breidge Boyle; Lolkje de Jong-van den Berg; Helen Dolk
Journal:  Eur J Epidemiol       Date:  2015-07-07       Impact factor: 8.082

3.  Patterns and predictors of treatment outcome for antenatal major depression.

Authors:  Tze-Ern Chua; John Carson Allen; Loretta Ang; Li Lian Ong; Ying Chia Ch'ng; Helen Chen
Journal:  Singapore Med J       Date:  2016-06-01       Impact factor: 1.858

Review 4.  Ondansetron and pregnancy: Understanding the data.

Authors:  Debra Kennedy
Journal:  Obstet Med       Date:  2015-12-23

Review 5.  Echinacea and elderberry-should they be used against upper respiratory tract infections during pregnancy?

Authors:  Lone Holst; Gro C Havnen; Hedvig Nordeng
Journal:  Front Pharmacol       Date:  2014-03-04       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.